Clinical Outcomes of Patients with EGFR T790M+NSCLC on Osimertinib

被引：0

作者：

Tan, W. L. ^{[1
]}

Hennedige, T. P. ^{[2
]}

Ng, Q. S. ^{[3
]}

Tan, S. H. ^{[4
]}

Tran, N. T. A. ^{[5
]}

Chua, B. J. G. ^{[6
]}

Toh, C. K. ^{[3
]}

Tan, E. H. ^{[3
]}

Tan, D. ^{[3
]}

Ang, M. ^{[3
]}

Kanesvaran, R. ^{[3
]}

Jain, A. ^{[3
]}

Lim, T. K. H. ^{[7
]}

Gogna, A. ^{[8
]}

Koh, M. ^{[9
]}

Yip, C. S. P. ^{[10
]}

Thng, C. H. ^{[2
]}

Chowbay, B. ^{[11
]}

Tan, M. H. ^{[3
]}

Lim, W. ^{[3
]}

机构：

[1] Natl Canc Ctr Singapore, Med Oncol, Singapore, Singapore

[2] Natl Canc Ctr Singapore, Oncol Imaging, Singapore, Singapore

[3] Natl Canc Ctr, Med Oncol, Singapore, Singapore

[4] Natl Canc Ctr Singapore, Clin Trial Off, Singapore, Singapore

[5] Moh Holdings, Diagnost Radiol, Singapore, Singapore

[6] Moh Holdings, Singapore, Singapore

[7] Singhealth, Anat Pathol, Singapore, Singapore

[8] Singhealth, Diagnost Radiol, Singapore, Singapore

[9] Singhealth, Pulmonol, Singapore, Singapore

[10] Natl Canc Ctr Singapore, Radiat Oncol, Singapore, Singapore

[11] Natl Canc Ctr Singapore, Med Sci & Clin Pharmacol, Singapore, Singapore

来源：

JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 11期

关键词：

EGFR T790M; osimertinib; NSCLC;

D O I：

10.1016/j.jtho.2017.09.1458

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P3.01-017

引用

页码：S2206 / S2206

页数：1

共 50 条

[31] ASTRIS a RWT with Osimertinib in NSCLC EGFR T790M Mutated: Disease Characteristics from Patients Included in Argentina
Biolchi, M.
Recondo, G.
Casalnuovo, M.
Tsou, F.
Diaz Perez, I.
Reinhold, F.
Martin, C.
JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (09) : S169 - S169
[32] Investigation of the mechanisms of resistance to osimertinib in patients with T790M-associated NSCLC
Stepanova, M.
Moiseenko, F.
Zhabina, A.
Klimenko, V.
Rysev, N.
Myslik, A.
Artemieva, E.
Shelekhova, K.
Bogdanov, A.
Volkov, N.
Moiseenko, V.
ANNALS OF ONCOLOGY, 2019, 30
[33] Osimertinib benefit in EGFR-mutant NSCLC patients with T790M-mutation detected by circulating tumour DNA
Remon, J.
Caramella, C.
Jovelet, C.
Lacroix, L.
Lawson, A.
Smalley, S.
Howarth, K.
Gale, D.
Green, E.
Plagnol, V.
Rosenfeld, N.
Planchard, D.
Bluthgen, M. V.
Gazzah, A.
Pannet, C.
Nicotra, C.
Auclin, E.
Soria, J. C.
Besse, B.
ANNALS OF ONCOLOGY, 2017, 28 (04) : 784 - 790
[34] EGFR T790M Mutation Detection and Osimertinib Treatment Response Evaluation by Liquid Biopsy in Advanced NSCLC Patients
Li, C.
Liu, H.
Zhang, B.
Zhang, Z.
Su, Y.
Wang, C.
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2141 - S2142
[35] EGFR T790M resistance mutation in NSCLC: Real-life data of Austrian patients treated with osimertinib
Holzer, Sophia
Hochmair, Maximilian
Filipits, Martin
Mohn-Staudner, Andrea
Errhalt, Peter
Absenger, Gudrun
Bundalo, Tatjana
Arns, Britt-Madelaine
Setinek, Ulrike
Mikes, Romana
Kolb, Rainer
Schumacher, Michael
Zoechbauer-Mueller, Sabine
Patocka, Kurt
Haslbauer, Ferdinand
Rudzki, Jakob
Burghuber, Otto Chris
WIENER KLINISCHE WOCHENSCHRIFT, 2016, 128 (19-20) : 769 - 770
[36] Monitoring of EGFR Mutations During Osimertinib Treatment in Advance EGFR-Mutant T790M Positive NSCLC
Mohorcic, K.
Janzic, A.
Janzic, U.
Rot, M.
Kern, I.
JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S557 - S558
[37] The efficacy and toxicity of osimertinib in T790M-positive NSCLC with acquired resistance to EGFR-TKI in clinical practice.
Sonoda, Tomoaki
Yanagitani, Noriko
Saiki, Masafumi
Ariyasu, Ryo
Koyama, Junji
Takano, Natsuki
Kawashima, Yosuke
Oguri, Tomoyo
Nishikawa, Shingo
Kitazono, Satoru
Ohyanagi, Fumiyoshi
Horiike, Atsushi
Nishio, Makoto
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[38] Osimertinib in EGFR T790M-Positive Lung Cancer
Nishino, Mizuki
Hatabu, Hiroto
NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (20): : 1992 - 1993
[39] Clinical outcomes in Black patients with EGFR-mutated NSCLC treated with osimertinib
Belani, Neel
Rizwan, Farsha
Hasler, Jill
Bauman, Jessica
Mitchell, Khadijah
Borghaei, Hossein
Bodor, Joseph N.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2024, 33 (09)
[40] Osimertinib for EGFR-Mutant NSCLC Patients With Acquired T790M and EGFR Amplification After First-Generation EGFR-TKI Resistance
Zhang, Yidan
Xu, Yingqi
Xu, Jianlin
Zhong, Hua
Xia, Jinjing
Zhong, Runbo
CANCER SCIENCE, 2024,

← 1 2 3 4 5 →